360Dx

BioMerieux, Banyan Biomarkers Partner to Commercialize TBI Test

Jan 19, 2017

NEW YORK (360Dx) – BioMérieux said today it has signed a deal to commercialize Banyan Biomarkers' tests for diagnosing traumatic brain injuries (TBI).

Under the terms of the agreement, BioMérieux will make a $7 million equity investment in Banyan in exchange for rights to commercialize Banyan's TBI tests for global use as in vitro diagnostics on BioMérieux's VIDAS immunoassay platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

BioMerieux, Banyan Biomarkers Partner to Commercialize TBI Test

To read the full story....

Breaking News

FDA Grants Emergency Use Authorizations for Quadrant Biosciences, KimForest Coronavirus Tests

BARDA Awards $684K to Luminex for Enhanced COVID-19 Multiplex Antibody Test

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

Centogene Reports 13 Percent Decline in Q2 Revenues

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

BioReference Settles False Claims, Kickback Allegations for $11.5M

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

BioReference Settles False Claims, Kickback Allegations for $11.5M

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

Sponsorships